| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $2.07B | -4.0% |
| Cost of Revenue | $1.03B | -1.4% |
| Gross Profit | $1.04B | -6.5% |
| R&D Expense | $165.0M | +0.9% |
| SG&A Expense | $616.6M | +11.7% |
| Operating Income | -$1.18B | -357.4% |
| Pre-tax Income | -$1.22B | -381.2% |
| Income Tax | $6.1M | -92.2% |
| Net Income | -$1.22B |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $318.8M | — |
| Accounts Receivable | $285.3M | -2.9% |
| Inventory | $301.6M | +6.6% |
| Current Assets | $976.1M | +57.8% |
| Total Assets | $3.82B | -19.0% |
| Current Liabilities | $1.16B | +117.3% |
| Long-term Debt | $1.15B | — |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $397.6M | -12.5% |
| Capital Expenditures | $39.2M | +14.3% |
| Investing Cash Flow | -$37.7M | +97.8% |
| Financing Cash Flow | -$54.7M | -104.3% |
| Free Cash Flow | $358.4M | -14.7% |
| -444.8% |
| EPS (Basic) | -$10.84 | -444.1% |
| EPS (Diluted) | -$10.84 | -444.1% |
| Total Liabilities |
| $2.19B |
| +128.7% |
| Stockholders' Equity | $1.63B | -56.6% |